# NHS Aflibercept Treat and Extend Protocol v1.0
# ALL parameters must be explicitly defined - no defaults allowed
# Based on NHS wet AMD cost calculator data

name: "NHS Aflibercept Treat and Extend"
version: "1.0"
created_date: "2025-01-13"
author: "NHS Analysis Team"
description: "NHS-based treat-and-extend protocol for aflibercept derived from wet AMD cost calculator"

# Protocol timing parameters (NO DEFAULTS)
protocol_type: "treat_and_extend"
min_interval_days: 28  # 4 weeks - NHS minimum between injections
max_interval_days: 112  # 16 weeks - NHS data shows max extension to Q16W
extension_days: 28  # 4 weeks - NHS typically extends by 4-week increments
shortening_days: 14  # 2 weeks - reduce interval on disease activity

# NHS injection frequency by year (from wet AMD calculator)
nhs_annual_injections:
  year_1: 8.0  # Loading + monthly (3 loading + 5 additional)
  year_2: 6.0  # Extending intervals
  year_3: 5.0  # Further extension
  year_4: 4.0  # Stable patients
  year_5: 4.0  # Maintained frequency

# Disease state transitions - based on NHS treatment patterns
disease_transitions:
  NAIVE:
    NAIVE: 0.0        # Cannot remain naive after first assessment
    STABLE: 0.25      # 25% achieve early stability (NHS optimistic)
    ACTIVE: 0.65      # 65% have active disease requiring regular treatment
    HIGHLY_ACTIVE: 0.1  # 10% have aggressive disease
  STABLE:
    NAIVE: 0.0        # Cannot return to naive
    STABLE: 0.80      # 80% remain stable (NHS maintenance success)
    ACTIVE: 0.18      # 18% develop recurrence
    HIGHLY_ACTIVE: 0.02  # 2% rapid progression (rare)
  ACTIVE:
    NAIVE: 0.0        # Cannot return to naive
    STABLE: 0.15      # 15% achieve stability with treatment
    ACTIVE: 0.75      # 75% remain active (majority)
    HIGHLY_ACTIVE: 0.1  # 10% progress despite treatment
  HIGHLY_ACTIVE:
    NAIVE: 0.0        # Cannot return to naive
    STABLE: 0.03      # 3% dramatic improvement (very rare)
    ACTIVE: 0.12      # 12% partial response
    HIGHLY_ACTIVE: 0.85  # 85% remain highly active

# Treatment effect on disease transitions
# Modified to reflect NHS real-world effectiveness
treatment_effect_on_transitions:
  NAIVE:
    # No effect - naive always transitions regardless of treatment
    multipliers: {}
  STABLE:
    # Treatment helps maintain stability
    multipliers:
      STABLE: 1.15     # 15% more likely to stay stable with treatment
      ACTIVE: 0.85     # 15% less likely to become active
  ACTIVE:
    # Treatment promotes improvement but less than trial data
    multipliers:
      STABLE: 1.5      # 50% more likely to become stable
      ACTIVE: 0.85     # 15% less likely to stay active
      HIGHLY_ACTIVE: 0.6  # 40% less likely to worsen
  HIGHLY_ACTIVE:
    # Limited treatment effect in severe disease
    multipliers:
      STABLE: 1.5      # 50% more likely to improve dramatically
      ACTIVE: 1.3      # 30% more likely to improve
      HIGHLY_ACTIVE: 0.85  # 15% less likely to remain severe

# Vision change model - ETDRS letter changes per visit
# Based on NHS real-world outcomes (more conservative than trials)
vision_change_model:
  naive_treated:
    mean: 0    # First visit, no change yet
    std: 1
  naive_untreated:
    mean: -3   # Untreated naive patients lose vision faster
    std: 2
  stable_treated:
    mean: 0.5  # Small improvement when stable
    std: 1
  stable_untreated:
    mean: -0.5 # Gradual decline without treatment
    std: 1
  active_treated:
    mean: -1.5 # Moderate loss despite treatment
    std: 2
  active_untreated:
    mean: -4   # Significant loss without treatment
    std: 3
  highly_active_treated:
    mean: -3   # Substantial loss with treatment
    std: 3
  highly_active_untreated:
    mean: -6   # Severe loss without treatment
    std: 4

# Baseline vision distribution (ETDRS letters)
# NHS population tends to present later than trials
baseline_vision_distribution:
  type: normal
  mean: 65      # Lower than trial populations
  std: 12       # More variation in NHS practice
  min: 20       # Legal blindness threshold
  max: 85       # Good vision rare at presentation

# Discontinuation rules - based on NHS data (~15% annual)

# Clinical improvements - optional enhancements for realism
# Set enabled: true to activate all improvements
clinical_improvements:
  enabled: false
  use_loading_phase: true
  use_time_based_discontinuation: true
  use_response_based_vision: true
  use_baseline_distribution: false
  use_response_heterogeneity: true
  loading_phase_parameters:
    loading_injections: 3
    loading_interval_days: 28
  discontinuation_parameters:
    annual_probabilities:
      1: 0.125
      2: 0.15
      3: 0.12
      4: 0.08
      5: 0.075
  vision_response_parameters:
    loading:
      mean: 3.0
      std: 1.0
    year1:
      mean: 0.5
      std: 0.5
    year2:
      mean: 0.0
      std: 0.5
    year3plus:
      mean: -0.2
      std: 0.3
  response_types:
    good:
      probability: 0.3
      multiplier: 1.2
    average:
      probability: 0.5
      multiplier: 1.0
    poor:
      probability: 0.2
      multiplier: 0.6

discontinuation_rules:
  # Poor vision criteria
  poor_vision_threshold: 35        # ETDRS letters
  poor_vision_probability: 0.12    # 12% chance per visit when below threshold
  
  # High injection burden criteria  
  high_injection_count: 24         # 2 years of monthly injections
  high_injection_probability: 0.03 # 3% chance per visit when above count
  
  # Long treatment duration criteria
  long_treatment_months: 36        # 3 years
  long_treatment_probability: 0.02 # 2% chance per visit after duration
  
  # Annual discontinuation rate target: ~15% (NHS data)
  # Types of discontinuation
  discontinuation_types:
    - "planned"      # Patient/doctor decision
    - "adverse"      # Due to adverse events
    - "ineffective"  # Treatment not working
    - "access"       # NHS-specific: capacity/geographic issues

# NHS-specific parameters
nhs_parameters:
  # Switching rates (from wet AMD calculator)
  annual_switch_rate: 0.15  # 15% switch to other anti-VEGF annually
  
  # Capacity constraints
  max_appointments_per_month: 100  # Typical NHS clinic capacity
  average_wait_new_patient_days: 14  # Target for new patients
  average_wait_follow_up_days: 7    # Target for follow-ups
  
  # Cost parameters (2025 NHS net prices)
  aflibercept_2mg_cost: 457    # £ per injection after discount
  aflibercept_8mg_cost: 339    # £ per injection after discount
  administration_cost: 120      # £ per injection visit
  oct_scan_cost: 80            # £ per OCT scan
  consultation_cost: 150       # £ per consultant visit

# Treatment schedule modifications for NHS
nhs_treatment_schedule:
  loading_phase:
    number_of_injections: 3
    interval_days: 28
  
  # Extension criteria more conservative than trials
  extension_criteria:
    stable_visits_required: 2    # Need 2 stable visits before extending
    max_extension_per_step: 28   # Maximum 4-week extension at once
  
  # NHS tends to cap at Q12W rather than Q16W in practice
  practical_max_interval_days: 84  # 12 weeks